Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives

European Journal of Pharmaceutical Sciences

Volumn 21, Issue 4, 2004, Pages 545-552

  Pau, A ^a   Asproni, B ^a   Boatto, G ^a   Grella, G E ^a   De Caprariis, P ^b   Costantino, L ^c   Pinna, G A ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Aldose reductase inhibitors; Diabetic complications; Thieno h cinnolinone carboxylic acids

Indexed keywords

4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 ACETIC ACID; 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 BUTYRIC ACID; 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 PROPIONIC ACID; 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 VALERIC ACID; 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]ONE 2 HEXANOIC ACID; 8 METHYL 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 ACETIC ACID; 8 METHYL 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 BUTYRIC ACID; 8 METHYL 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 HEXANOIC ACID; 8 METHYL 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 PROPIONIC ACID; 8 METHYL 4,4A,5,6 TETRAHYDROTHIENO[2,3 H]CINNOLIN 3(2H) ONE 2 VALERIC ACID; ALDEHYDE REDUCTASE; KETONE DERIVATIVE; SORBINIL; TOLRESTAT; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; PHARMACOPHORE; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; ANIMALS; CARBOXYLIC ACIDS; ENZYME INHIBITORS; SWINE; THIOPHENES;

EID: 1442284442     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.12.005     Document Type: Article

References (17)

1. Bohren K.M., Bullock B., Wermuth B., Gabbay K.H. The aldo-keto reductase superfamily. cDNAs and deduced aminoacid sequences of human aldehyde and aldose reductases. J. Biol. Chem. 264:1989;9547-9551.
2. Costantino L., Rastelli G., Gamberoni M.C., Barlocco D. Pharmacological approaches to the treatment of diabetic complications. Exp. Opin. Ther. Patents. 10:2000;1245-1262.
3. Costantino L., Rastelli G., Vescovini K., Cignarella G., Vianello P., Del Corso A., Cappiello M., Mura U., Barlocco D. Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. J. Med. Chem. 39:1996;4396-4405.
4. Eggler, J.F., Larson, E.R., Lipinski, C.A., Mylari, B.L., Urban, F.G., 1993. In: Maryanoff, E., Maryanoff, C.A. (Eds.), Advances in Medicinal Chemistry, vol. 2. Jai Press Inc., London, England, pp. 197-246.
5. Kador P.F. The role of aldose reductase in the development of diabetic complications. Med. Res. Rev. 8:1988;325-352.
6. Kotsunori H., Miyata S., Ohara T., Liu B.-F., Urihara A., Kojima H., Suzuki K., Myiazaki H., Yamashita Y., Inaba K., Kasuga M. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes care. 26:2003;1889-1894.
7. Malamas M.S., Hohman T.C., Millen J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2- fluorophenyl)methyl]-6-fluorospiro-isoquinoline-[4(1H)-3′-pyrrolidine]-1, 2′,3,5′(2H)-tetrone and congeners. Part 1. J. Med. Chem. 37:1994;2043-2058.
8. Muscate, A., Kenion, G.L., 1995. Approaches to the rational design of enzyme inhibitors. In: Wolff, M. (Ed.), Burger's Medicinal Chemistry and Drug Discovery, vol. 1, Principles and Practice. Wiley, New York, p. 733.
9. Mylari B.L., Armento S.J., Beebe D.A., Conn E.L., Coutcher J.B., Dina M.S., O'Gorman M.T., Linhares M.C., Martin W.H., Oates D.J., Tess D.A., Withbroe G.J., Zembrowski W.J. A highly selective, non hydantoin, non carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2-H-pyridazin-3- one. J. Med. Chem. 46:2003;2283-2286.
10. Obrosova I.G., Fathallah I., Lang H.J., Greene D.A. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia. 42:1999;1187-1194.
11. Pinna G.A., Barlocco D. Synthesis and pharmacological evaluation of 4,4a,5,6-tetrahydro-2H-thieno[2,3-h]-cinnolin-3-ones bioisosters of antihypertensive and antithrombotic benzo[h]-cinnolinones. Eur. J. Med. Chem. 26:1991;787-790.
12. Sarges R., Oates P.J. Aldose reductase inhibitors: recent developments. Prog. Drug Res. 40:1993;99-156.
13. Sestany, F., Bellini, S., Fung, N., Abraham, A., Treasurywala, L., Humber, N.S., Duquesne, D., Dvornik, 1984. N-[[5-(trifluoromethyl)-6-methoxy-1- naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J. Med. Chem. 27, 255-256.
14. Tallarida, R.B., 1987. Murray, Manual of Pharmacological Calculations with Computer Programs, second ed. Springer, New York.
15. Tanaka H., Kirihara S., Yasumatsu H., Yakushiji T., Nakao T. Synthesis and evaluation of novel 2-aryl-2,5,6,7-tetrahydro-3H-thieno[2′,3′:6, 7]cyclohepta[1,2-c]pyridazin-3-ones and 2-aryl-5,6-dihydrothieno[2,3-h]cinnolin- 3(2H)-ones as anxiolytics. Eur. J. Med. Chem. Chim. Ther. 32:1997;607-615.
16. Wilson, D.K., Qhiocho, F.A., Petrash, J.M., 1997. Structural studies of aldose reductase inhibition. In: Veerapandian, P. (Ed.), Structure-Based Drug Design. Marcel Dekker, New York, pp. 229-246.
17. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev. 50:1998;21-33.